The Effects of Tumumab on the Survival of MRT-Negative Patients

About 50% of the patients with, you know, the primary intention who entered the study were MRT-negative per flow cytometry at that stage. So even with a lower intensity backbone, these patients still had an fair amount get to MRT- negative activity. The curves, as was hinted at, looked, looked fantastic. Median overall survival in the blend of Tumumab, MRT- Negative arm was not reached and the chemotherapy alone arm was still quite good at 71 plus months,. And in the chemotherapy arm, there were 39 events for, for deaths versus 17 and the chemotherapy plus blend ofTumumab arm.